Enteric coating liquid

Claim 2

An enteric coating liquid comprising an alkali metal salt of an acid having an acid dissociation constant (pKa) of at least 3 at 25° C. and a water-insoluble oxycarboxylic acid type cellulose derivative dispersed in water or a mixture of water and at most 20% by weight of a lower alcohol having 1 to 3 carbon atoms, said water-insoluble oxycarboxylic acid type cellulose derivative being derived from cellulose or a hydroxyalkyl cellulose by replacing up to three hydroxyl groups per glucose unit skeleton with at least two kinds of substituents, at least one substituent being selected from the group consisting of a carboxyalkyl ether group of the formula: --OC n H 2n COOH and a half ester group based on a dicarboxylic acid, and at least one substituent being selected from the group consisting of an ether group of the formula: --OC n H 2n+1 and an ester group of the formula: --OOCR, wherein the alkyl in the hydroxyalkyl cellulose is a C 1 to C 5 alkyl, n is an integer of 1 to 5 and R is a C 1 to C 5 alkyl or a higher fatty acid residue.

Claim 3

The enteric coating liquid of claim 1, wherein said water-insoluble oxycarboxylic acid type cellulose derivative is a carboxyalkyl methyl cellulose or carboxyalkyl ethyl cellulose wherein the alkyl is a C 1 to C 5 alkyl.

Claim 4

The enteric coating liquid of claim 1, wherein the content of said oxycarboxylic acid type cellulose derivative is from 5 to 30% by weight.

Claim 5

The enteric coating liquid of claim 1, wherein said alkali metal salt is included in an amount of at most 30% by weight based on the oxycarboxylic acid type cellulose derivative.

Claim 6

An enteric coated pharmaceutical obtained by treating a pharmaceutical with a continuous film formed from an aqueous dispersion containing as essential components an alkali metal salt of an acid having an acid dissociation constant (pKa) of at least 3 at 25° C. and a water-insoluble oxycarboxylic acid type cellulose derivative in water or a water-alcohol mixed solvent containing at most 20% by weight of alcohol, said water-insoluble oxycarboxylic acid type cellulose derivative being derived from cellulose or a hydroxyalkyl cellulose by replacing up to three hydroxyl groups per glucose unit skeleton with at least two kinds of substituents, at least one substituent being selected from the group consisting of a carboxyalkyl ether group of the formula: --OC n H 2n COOH and a half ester group based on a dicarboxylic acid, and at least one substituent being selected from the group consisting of an ether group of the formula: --OC n H 2n+1 and an ester group of the formula: --OOCR, wherein the alkyl in the hydroxyalkyl cellulose is a C 1 to C 5 alkyl, n is an integer of 1 to 5 and R is a C 1 to C 5 alkyl or a higher fatty acid residue.

Claim 7

An enteric coated pharmaceutical obtained by treating a pharmaceutical with a continuous film formed from an aqueous dispersion containing as essential components an alkali metal salt of an acid having an acid dissociation constant (pKa) of at least 3 at 25° C. and a water-insoluble oxycarboxylic acid type cellulose derivative in water or a water-alcohol mixed solvent containing at most 20% by weight of alcohol, said water-insoluble oxycarboxylic acid type cellulose derivative being derived from cellulose or a hydroxyalkyl cellulose by replacing up to three hydroxyl groups per glucose unit skeleton with at least two kinds of substituents, at least one substituent being selected from the group consisting of a carboxyalkyl ether group of the formula: --OC n H 2n COOH and a half ester group based on a dicarboxylic acid, and at least one substituent being selected from the group consisting of an ether group of the formula: --OC n H 2n+1 and an ester group of the formula: --OOCR, wherein the alkyl in the hydroxyalkyl cellulose is a C 1 to C 5 alkyl, n is an integer of 1 to 5 and R is a C 1 to C 5 alkyl or a higher fatty acid residue.